| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $0 ) |
| | 2026 | 2023 | CYTEX THERAPEUTICS INC | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | R41AR083778 | Addressing bone marrow lesions that compromise osteochondral tissue repair | 000 | 1 | NIH | 2/26/2026 | $0 |
|
| Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2024 | CYTEX THERAPEUTICS INC | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | SB1AR066439 | Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model | 000 | 6 | NIH | 7/29/2025 | $0 |
| | 2025 | 2023 | CYTEX THERAPEUTICS INC | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | R44AG059310 | Cartilage Regeneration with Tunable Inflammation Resistance | 001 | 5 | NIH | 5/30/2025 | $0 |
| | 2025 | 2023 | CYTEX THERAPEUTICS INC | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | R44AG059310 | Cartilage Regeneration with Tunable Inflammation Resistance | 000 | 5 | NIH | 4/10/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $399,998 ) |
| | 2024 | 2024 | CYTEX THERAPEUTICS INC | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | SB1AR066439 | Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model | 000 | 6 | NIH | 7/31/2024 | $399,998 |
| | 2024 | 2023 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | R41AR083778 | Addressing bone marrow lesions that compromise osteochondral tissue repair | 000 | 1 | NIH | 10/17/2023 | $0 |
| | 2024 | 2023 | CYTEX THERAPEUTICS INC | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | R44AG059310 | Cartilage Regeneration with Tunable Inflammation Resistance | 000 | 5 | NIH | 5/8/2024 | $0 |
| | 2024 | 2021 | CYTEX THERAPEUTICS INC | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | R44AR077467 | A Treatment Paradigm for Femoracetabular Impingement (FAI) | 000 | 2 | NIH | 1/26/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $1,260,607 ) |
| | 2023 | 2023 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | SB1AR066439 | Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model | 000 | 5 | NIH | 8/3/2023 | $399,998 |
| | 2023 | 2023 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | R41AR083778 | Addressing bone marrow lesions that compromise osteochondral tissue repair | 000 | 1 | NIH | 9/18/2023 | $282,265 |
| | 2023 | 2023 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | R44AG059310 | Cartilage Regeneration with Tunable Inflammation Resistance | 001 | 5 | NIH | 6/12/2023 | $578,372 |
| | 2023 | 2021 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | R44AG059310 | Cartilage Regeneration with Tunable Inflammation Resistance | 000 | 4 | NIH | 6/9/2023 | $0 |
| | 2023 | 2019 | CYTEX THERAPEUTICS INC | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | SB1AR061916 | A crosslinked cartilage-derived matrix for cartilage tissue engineering | 000 | 6 | NIH | 11/21/2022 | -$28 |
|
| Issue Date FY: 2022 ( Subtotal = $400,000 ) |
| | 2022 | 2022 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | SB1AR066439 | Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model | 000 | 4 | NIH | 9/20/2022 | $400,000 |
| | 2022 | 2021 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | R44AG059310 | Cartilage Regeneration with Tunable Inflammation Resistance | 000 | 4 | NIH | 4/21/2022 | $0 |
| | 2022 | 2019 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | SB1AR061916 | A crosslinked cartilage-derived matrix for cartilage tissue engineering | 000 | 6 | NIH | 2/18/2022 | $0 |
| | 2022 | 2019 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | SB1AG059313 | Functional Tissue Engineering for Cartilage Repair | 000 | 6 | NIH | 10/26/2021 | $0 |
| | 2022 | 2019 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | R41AR074837 | Regenerative rotator cuff repair in a clinically relevant chronic disease model | 000 | 1 | NIH | 2/17/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $2,133,159 ) |
| | 2021 | 2021 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | R44AG059310 | Cartilage Regeneration with Tunable Inflammation Resistance | 001 | 4 | NIH | 6/3/2021 | $1,283,733 |
| | 2021 | 2021 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | R44AR077467 | A Treatment Paradigm for Femoracetabular Impingement (FAI) | 001 | 2 | NIH | 5/28/2021 | $849,426 |
| | 2021 | 2020 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | R44AR077467 | A Treatment Paradigm for Femoracetabular Impingement (FAI) | 000 | 1 | NIH | 4/22/2021 | $0 |
| | 2021 | 2018 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | R44AG059310 | Cartilage Regeneration with Tunable Inflammation Resistance | 000 | 2 | NIH | 4/19/2021 | $0 |
| | 2021 | 2018 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | R43AR073716 | Evaluating the Safety and Efficacy of Cartilage Regeneration with Tunable Inflammation Resistance | 000 | 1 | NIH | 6/28/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $2,327,859 ) |
| | 2020 | 2020 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | R44AR077467 | A Treatment Paradigm for Femoracetabular Impingement (FAI) | 000 | 1 | NIH | 6/1/2020 | $829,606 |
| | 2020 | 2020 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | R44AG059310 | Cartilage Regeneration with Tunable Inflammation Resistance | 002 | 3 | NIH | 9/18/2020 | $1,498,253 |
| | 2020 | 2019 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | R41AR074837 | Regenerative rotator cuff repair in a clinically relevant chronic disease model | 000 | 1 | NIH | 11/15/2019 | $0 |
| | 2020 | 2019 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | R41AR074837 | Regenerative rotator cuff repair in a clinically relevant chronic disease model | 000 | 1 | NIH | 11/15/2019 | $0 |
| | 2020 | 2018 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | R43AR073716 | Evaluating the Safety and Efficacy of Cartilage Regeneration with Tunable Inflammation Resistance | 000 | 1 | NIH | 7/20/2020 | $0 |
| | 2020 | 2018 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | R44AG059310 | Cartilage Regeneration with Tunable Inflammation Resistance | 001 | 2 | NIH | 9/18/2020 | $0 |
| | 2020 | 2018 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | R44AG059310 | Cartilage Regeneration with Tunable Inflammation Resistance | 000 | 2 | NIH | 4/28/2020 | $0 |
| | 2020 | 2018 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | R42AR066439 | Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model | 000 | 3 | NIH | 8/12/2020 | $0 |
| | 2020 | 2017 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | R43AR072166 | A 3D osteoarthritis model targeting patient populations with high risk genetic polymorphisms | 000 | 1 | NIH | 1/14/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,008,308 ) |
| | 2019 | 2019 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | SB1AR061916 | A crosslinked cartilage-derived matrix for cartilage tissue engineering | 000 | 6 | NIH | 8/21/2019 | $400,000 |
| | 2019 | 2019 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | R41AR074837 | Regenerative rotator cuff repair in a clinically relevant chronic disease model | 000 | 1 | NIH | 9/9/2019 | $169,570 |
| | 2019 | 2019 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | SB1AG059313 | Functional Tissue Engineering for Cartilage Repair | 000 | 6 | NIH | 5/6/2019 | $383,308 |
| | 2019 | 2019 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | R41AR074837 | Regenerative rotator cuff repair in a clinically relevant chronic disease model | 000 | 1 | NIH | 9/9/2019 | $55,430 |
| | 2019 | 2018 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | R43AR073716 | Evaluating the Safety and Efficacy of Cartilage Regeneration with Tunable Inflammation Resistance | 000 | 1 | NIH | 11/30/2018 | $0 |
| | 2019 | 2018 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | R44AG059310 | Cartilage Regeneration with Tunable Inflammation Resistance | 000 | 2 | NIH | 12/3/2018 | $0 |
| | 2019 | 2016 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | SB1AR055414 | Hip-Joint Resurfacing with Functional Human Cartilage | 000 | 4 | NIH | 12/28/2018 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $2,324,842 ) (Continued on the next page) |
| | 2018 | 2018 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | SB1AG059313 | Functional Tissue Engineering for Cartilage Repair | 000 | 5 | NIH | 5/21/2018 | $382,964 |
| | 2018 | 2018 | CYTEX THERAPEUTICS, INC. | 2609 N DUKE ST STE 303A | DURHAM | NC | 27704-3048 | DURHAM | USA | SB1AR061916 | A crosslinked cartilage-derived matrix for cartilage tissue engineering | 001 | 5 | NIH | 8/21/2018 | $399,997 |
|
